法国抗肿瘤治疗及泌尿系肿瘤相关肾衰竭的趋势与结局
基于法国REIN登记2003-2015年数据,肾毒性药物相关肾衰竭287例,泌尿系肿瘤相关肾衰竭1157例。年龄性别调整发病率分别为0.43和1.80/百万居民,2006-2015年年增幅5%和2%。匹配对照后,活动性恶性肿瘤患者死亡风险显著增高,而无活动性恶性肿瘤者死亡风险未显著增加,但肾移植等待名单准入均显著降低。
要点
- 肾毒性药物及泌尿系肿瘤相关肾衰竭发病率逐年上升。
- 无活动性恶性肿瘤者透析起始死亡风险未显著增加。
- 两类患者肾移植等待名单准入均显著低于对照。
核心结论
- 癌症相关肾衰竭缓慢但持续增加。
- 透析起始时无活动性恶性肿瘤者死亡风险未显著增加,但肾移植准入仍受限。
研究设计与样本
- 基于法国REIN登记2003-2015年数据的回顾性队列研究。
- 肾毒性药物相关肾衰竭287例,泌尿系肿瘤相关肾衰竭1157例,匹配对照11678例。
主要发现
- 肾毒性药物相关肾衰竭年龄性别调整发病率为0.43/百万居民(95%CI 0.38-0.49),泌尿系肿瘤相关为1.80/百万居民(95%CI 1.68-1.90)。
- 2006-2015年两类肾衰竭发病率分别年增5%和2%。
- 活动性恶性肿瘤患者死亡SHR:肾毒性药物相关4.2(95%CI 3.2-5.5),泌尿系肿瘤相关2.0(95%CI 1.7-2.2)。
- 无活动性恶性肿瘤患者死亡SHR:肾毒性药物相关1.4(95%CI 1.0-2.0),泌尿系肿瘤相关1.1(95%CI 0.9-1.2)。
- 肾移植等待名单准入SHR:肾毒性药物相关活动性肿瘤0.19(95%CI 0.11-0.32)、无活动性肿瘤0.62(95%CI 0.43-0.88);泌尿系肿瘤活动性0.28(95%CI 0.21-0.37)、无活动性0.47(95%CI 0.36-0.60)。
关键数值与推荐
- 肾毒性药物相关肾衰竭年龄性别调整发病率0.43/百万居民(95%CI 0.38-0.49)。
- 泌尿系肿瘤相关肾衰竭年龄性别调整发病率1.80/百万居民(95%CI 1.68-1.90)。
临床怎么用
- 对接受抗肿瘤治疗或泌尿系肿瘤患者应监测肾功能,警惕肾衰竭发生。
- 无活动性恶性肿瘤的肾衰竭患者应积极评估肾移植候选资格,因其死亡风险未显著增加但移植准入受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Cancer survival is improving along with an increase in the potential for adverse kidney effects from antineoplastic treatments or nephrectomy. We sought to describe recent trends in the incidence of kidney failure related to antineoplastic treatments and urinary tract cancers and evaluate patient survival and kidney transplantation access. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used the French Renal Epidemiology and Information Network registry to identify patients with kidney failure related to antineoplastic treatments or urinary tract cancer from 2003 to 2015. We identified 287 and 1157 cases with nephrotoxin- and urinary tract cancer-related kidney failure, respectively. The main study outcomes were death and kidney transplantation. After matching cases to two to ten controls (n=11,678) with other kidney failure causes for age, sex, year of dialysis initiation, and diabetes status, we estimated subdistribution hazard ratios (SHR) of each outcome separately for patients with and without active malignancy. RESULTS: The mean age- and sex-adjusted incidence of nephrotoxin-related kidney failure was 0.43 (95% CI, 0.38 to 0.49) per million inhabitants and 1.80 (95% CI, 1.68 to 1.90) for urinary tract cancer-related kidney failure; they increased significantly by 5% and 2% annually, respectively, during 2006-2015. Compared with matched controls, age-, sex-, and comorbidity-adjusted SHRs for mortality in patients with nephrotoxin-related kidney failure were 4.2 (95% CI, 3.2 to 5.5) and 1.4 (95% CI, 1.0 to 2.0) for those with and without active malignancy, respectively; for those with urinary tract cancer, SHRs were 2.0 (95% CI, 1.7 to 2.2) and 1.1 (95% CI, 0.9 to 1.2). The corresponding SHRs for transplant wait-listing were 0.19 (95% CI, 0.11 to 0.32) and 0.62 (95% CI, 0.43 to 0.88) for nephrotoxin-related kidney failure cases and 0.28 (95% CI, 0.21 to 0.37) and 0.47 (95% CI, 0.36 to 0.60) for urinary tract cancer cases. Once on the waiting list, access to transplantation did not differ significantly between cases and controls. CONCLUSIONS: Cancer-related kidney failure is slowly but steadily increasing. Mortality does not appear to be increased among patients without active malignancy at dialysis start, but their access to kidney transplant remains limited.
引用
- Mansouri I, Alencar de Pinho N, Snanoudj R, et al. Trends and Outcomes with Kidney Failure from Antineoplastic Treatments and Urinary Tract Cancer in France. Clin J Am Soc Nephrol. 2020. PMID: 32144099. doi:10.2215/CJN.10230819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。